title: A method for maintaining the clinical results of 4% hydroquinone and 0.025% tretinoin with a cosmeceutical formulation.
abstract: Facial dyspigmentation treatment is an unmet need in dermatology with increasing challenges due to the questionable safety of hydroquinone. This research examined a new OTC formulation containing hydroxyphenoxy propionic acid, ellagic acid, yeast extract, and salicylic acid on subjects who previously completed 12 weeks of treatment with 4% hydroquinone and 0.025% retinoic acid. The goal of this study was to evaluate the skin lightening and tolerability profile of a 20-week maintanence therapy with a cosmeceutical formulation during the summer months. 33 healthy subjects ages 25-60 years with moderate facial dyspigmentation defined as a score of 3 on a 5-point scale were enrolled. There was statistically significant improvement at week 20 in terms of even skin tone (P<0.001), spot intensity (P<0.001), spot size (P<0.05) and overall hyperpigmentation (P>=0.002).
authors.forename: Zoe Diana
authors.initials: ZD
authors.lastname: Draelos
authors.forename: Susana
authors.initials: S
authors.lastname: Raab
authors.forename: Margarita
authors.initials: M
authors.lastname: Yatskayer
authors.forename: Nannan
authors.initials: N
authors.lastname: Chen
authors.forename: Yevgeniy
authors.initials: Y
authors.lastname: Krol
authors.forename: Christian
authors.initials: C
authors.lastname: Oresajo
mesh_terms: D000328:Adult; D000068937:Cosmeceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006873:Hydroquinones / Q000009:adverse effects / Q000627:therapeutic use*; D017495:Hyperpigmentation / Q000188:drug therapy / Q000473:pathology; D007641:Keratolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010859:Pigmentation Disorders / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D014212:Tretinoin / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000068937:Cosmeceuticals; D006873:Hydroquinones; D007641:Keratolytic Agents; D014212:Tretinoin; C031927:hydroquinone